Shattuck Labs price to book ratio STTK
Market value divided by the book value of the company's net assets, since 2021.
- Today, Nov 2, 2026
- 2.5×
- 6-year median
- 1.2×
- Against its 6-year history
- 65th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 0.4× to 6.7×
- Peer median
- 2.0×
Shattuck Labs' price to book ratio is 2.5× as of Nov 2, 2026.
That is above its 6-year median of 1.2×, higher than on 65% of days in the last 6 years.
Over that time it ranged from 0.4× in Oct 2023 to 6.7× in Apr 2026.
The median for 10 large drugmakers of a similar size is 2.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 2.5× | 2.5× | 6.7× |
| 2025 | 2.3× | 0.4× | 2.3× |
| 2024 | 0.6× | 0.5× | 4.0× |
| 2023 | 2.7× | 0.4× | 2.7× |
| 2022 | 0.5× | 0.4× | 1.2× |
| 2021 | 1.4× | 1.4× | 5.1× |
Against its peers
Companies in Drug Manufacturers - General nearest Shattuck Labs' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| STTKShattuck Labs | 2.5× |
| PBYIPuma Biotechnology | 3.8× |
| IRWDIronwood Pharmaceuticals | n/m |
| ARVNArvinas | 0.9× |
| ZVRAZevra Therapeutics | 2.8× |
| CRMDCorMedix | 0.9× |
| COLLCollegium Pharmaceutical | 2.5× |
| ABUSArbutus Biopharma | 3.1× |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| OMEROmeros | n/m |
| NATRNatures Sunshine Products | 1.2× |
| Peer median | 2.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Shattuck Labs
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.